RMD – UBS rates the stock as Neutral

ResMed will report its first-quarter results on 30 October. UBS forecasts revenue growth for US/Canada/Latin America to be 3%. Europe and Asia are expected to show a revenue growth of 5%. Gross margin is expected to be flat versus the fourth quarter and net profit is forecast to be up 12% versus last year. 

The broker also anticipates ventilator sales this quarter to be down circa -65% versus the June quarter although still well above pre-covid-19 levels.

Believing the fundamental drivers of longer-term growth remain intact, UBS maintains its Neutral rating with a target price of US$200.

Sector: Health Care Equipment & Services.

Current Price is $25.11. Target price not assessed.

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →